Rapid Communication
Copyright ©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 21, 2007; 13(23): 3221-3227
Published online Jun 21, 2007. doi: 10.3748/wjg.v13.i23.3221
Table 1 Clinico-pathological and biological parameters of patients
Characteristicsn (%)Deaths, n (%)RR (95% CI)
Males26 (83.9)14 (53.8)1.14 (0.36-3.57)
Age < 65 yr21 (67.7)12 (57.1)1 (0.37-2.70)
Cirrhosis29 (93.5)18 (62)21.85 (0-187.50)
HCV (+)16 (51.6)10 (62.5)0.80 (0.31-2.06)
Alcohol etiology13 (42.0)11 (84.6)0.62 (0.23-1.62)
Uninodular25 (80.6)15 (60)1.33 (0.37-4.74)
Size ≤ median mm21 (67.7)10 (47.6)4.73 (1.61-13.89)a
Alpha-fetoprotein ≥ 20 (ng/mL)12 (38.7)8 (66.6)1.46 (0.57-3.71)
Histopathology HCC-T28 (90.3)16 (55.1)1.35 (0.30-5.95)
AR (+)21 (67.7)10 (47.6)0.62 (0.25-1.68)
ER (+)16 (51.6)10 (62.5)1.05 (0.41-2.67)
PgR (+)26 (83.9)13 (50)0.26 (0.08-0.85)a
ApoD (+)12 (38.7)8 (66.6)1.47 (0.57-3.77)
Table 2 Relationship between AR and ER Immunostaining values and Clinico-Pathological Characteristics
CharacteristicsAndrogen receptors (AR)
Estrogen receptors (ER)
n (%)Score valuesmedian (range)n (%)Score valuesmedian (range)
Males18 (69.2)4.1 (0-229.5)12 (46.2)8.5 (0-65)
Age < 65 yr15 (71.4)6.7 (0-52)10 (47.6)8.5 (0-65)
Cirrhosis19 (65.5)4.2 (0-229.5)16 (55.2)8.5 (0-65)
VHC (+)11 (68.8)4.2 (0-229.5)11 (68.8)8.75 (0-65)
Alcohol etiology7 (53.8)3.7 (0-52)3 (23.1)0 (0-65)
Uninodular16 (64)4.2 (0-229.5)13 (52)8.5 (0-65)
Tumor size
< median13 (61.9)4 (0-229.5)12 (57.1)8.5 (0-65)
≥ median8 (80)5.75 (0-16)4 (40)8.7 (0-15.75)
Alfa-fetoprotein (ng/mL)
< 2012 (63.2)4 (0-229.5)8 (42.1)8.5 (0-65)
≥ 209 (75)5.7 (0-31)8 (66.7)8.7 (0-16)
Histopathology
HCC-T20 (71.4)4.5 (0-229.5)15 (53.6)8.5 (0-65)
Non HCC-T1 (33.3)1 (0-26.25)1 (33.3)0 (0-20.5)
Death
No11 (84.6)12 (0-229.5)6 (46.2)9 (0-65)
Yes10 (55.6)4 (0-28.75)10 (55.6)8.5 (0-20.5)
Androgen receptors
Negative--3 (30)0 (0-20.5)a
Positive13 (61.9)9 (0-65)
Estrogen receptors
Negative8 (53.3)3.2 (0-29)--
Positive13 (81.3)8.4 (0-229.5)
Progesterone receptors
Negative0 (0)c1.7 (0-4.2)a1 (20)0 (0-8.5)a
Positive21 (80.8)8.4 (0-229.5)15 (57.7)9 (0-65)
Apo D
Negative13 (68.4)4.2 (0-52)10 (52.6)8.5 (0-65)
Positive8 (66.7)4.2 (0-229.5)6 (50)8.5 (0-65)
Table 3 Relationship between PgR and Apo D Immunostaining values and clinico-pathological characteristics
Progesterone receptors (PgR)
Apolipoprotein-D (Apo D)
Characteristicsn (%)Score(median-range)n (%)Score(median-range)
Males22 (84.6)13.7 (0-61)10 (28.5)0 (0-81.1)
Age < 65 yr17 (81)9.7 (0-61)7 (33.3)0 (0-69.5)
Cirrhosis24 (82.8)14 (0-61)11 (37.9)0 (0-81.1)
HCV (+)15 (93.8)15.9 (3-61)8 (50)11 (0-81.11)
Alcohol etiology11 (84.6)9.7 (0-25)5 (38.5%)0 (0-80.4)
Uninodular20 (80)13.7 (0-61)11 (44)0 (0-81.1)
Size < median17 (81)13.7 (0-61)6 (28.6)0 (0-80.4)
Alfa-fetoprotein ≥
20 (ng/mL)11 (91.7)14 (5.7-61)3 (25)0 (0-80.4)
Histopathology
HCC-T23 (82.1)13.7 (0-61)11 (39.3)0 (0-81.1)
Death rate13 (72.2)11.75 (0-61)8 (44.4)0 (0-81.1)
Androgen receptors
Negative5 (50)c9.6 (0-20)a4 (40)0 (0-80.4)
Positive21 (100)14.2 (4-61)8 (38.1)0 (0-81.1)
Estrogen receptors
Negative11 (73.3)8 (0-34)a6 (40)0 (0-81.1)
Positive15 (93.8)17.2 (3-61)6 (37.5)0 (0-80.4)
Pg receptors
Negative--2 (40)0 (0-24.4)
Positive10 (38.5)0 (0-81.1)
ApoD
Negative16 (84.2)13.7 (0-61)--
Positive10 (83.3)13.8 (3-34)